Hao‐Yi Li

892 total citations
21 papers, 642 citations indexed

About

Hao‐Yi Li is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Hao‐Yi Li has authored 21 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 6 papers in Cancer Research and 4 papers in Oncology. Recurrent topics in Hao‐Yi Li's work include DNA Repair Mechanisms (4 papers), Mitochondrial Function and Pathology (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Hao‐Yi Li is often cited by papers focused on DNA Repair Mechanisms (4 papers), Mitochondrial Function and Pathology (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). Hao‐Yi Li collaborates with scholars based in Taiwan, Germany and France. Hao‐Yi Li's co-authors include Pei‐Jung Lu, Marcus J. Calkins, Michael Hsiao, Yu‐Chia Chen, Cheng‐Han Lin, Chia-Ning Yang, Luo-Ping Ger, Forn-Chia Lin, Hui‐Ling Chen and Tai‐I Hsu and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Hao‐Yi Li

21 papers receiving 639 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hao‐Yi Li Taiwan 15 472 231 129 100 62 21 642
Yuxin Qin China 9 633 1.3× 151 0.7× 184 1.4× 91 0.9× 63 1.0× 13 812
Jing-Yuan Liu United States 11 384 0.8× 141 0.6× 228 1.8× 64 0.6× 28 0.5× 13 576
Boon Shing Tan Malaysia 12 421 0.9× 186 0.8× 181 1.4× 41 0.4× 25 0.4× 18 645
Jean‐François Gaussin Belgium 7 343 0.7× 80 0.3× 114 0.9× 134 1.3× 59 1.0× 10 587
Sundar Neelakantan United States 9 569 1.2× 403 1.7× 149 1.2× 99 1.0× 57 0.9× 15 830
Valentina Pileczki Romania 15 414 0.9× 267 1.2× 125 1.0× 54 0.5× 27 0.4× 27 666
Jacqueline Keßler Germany 14 364 0.8× 156 0.7× 77 0.6× 62 0.6× 40 0.6× 25 514
Zhiyu Li China 12 358 0.8× 114 0.5× 128 1.0× 33 0.3× 58 0.9× 25 496
Małgorzata Sztiller-Sikorska Poland 16 405 0.9× 162 0.7× 157 1.2× 42 0.4× 27 0.4× 21 537
Kwang-Rok Kim South Korea 12 382 0.8× 173 0.7× 199 1.5× 57 0.6× 22 0.4× 14 692

Countries citing papers authored by Hao‐Yi Li

Since Specialization
Citations

This map shows the geographic impact of Hao‐Yi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao‐Yi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao‐Yi Li more than expected).

Fields of papers citing papers by Hao‐Yi Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hao‐Yi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao‐Yi Li. The network helps show where Hao‐Yi Li may publish in the future.

Co-authorship network of co-authors of Hao‐Yi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Hao‐Yi Li. A scholar is included among the top collaborators of Hao‐Yi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hao‐Yi Li. Hao‐Yi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shen, Chih‐Jie, Amandeep Thakur, I‐Chung Chen, et al.. (2025). Contribution of Prostaglandin E2‐Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood–Brain Barrier Crossing Celecoxib Derivative. Advanced Science. 12(38). e06336–e06336. 1 indexed citations
2.
Weickert, Pedro, et al.. (2024). Electro-elution-based purification of covalent DNA–protein cross-links. Nature Protocols. 19(10). 2891–2914. 6 indexed citations
3.
Weickert, Pedro, Almudena Serrano-Benítez, Hao‐Yi Li, et al.. (2024). Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS. The EMBO Journal. 43(12). 2397–2423. 12 indexed citations
4.
Weickert, Pedro, Hao‐Yi Li, Shubo Zhao, et al.. (2023). SPRTN patient variants cause global-genome DNA-protein crosslink repair defects. Nature Communications. 14(1). 352–352. 20 indexed citations
5.
Li, Hao‐Yi, et al.. (2023). Mitochondrial Mechanisms in Temozolomide Resistance: Unraveling the Complex Interplay and Therapeutic Strategies in Glioblastoma. Mitochondrion. 75. 101836–101836. 7 indexed citations
6.
Kao, Tzu‐Jen, et al.. (2023). Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities. Lipids in Health and Disease. 22(1). 114–114. 15 indexed citations
7.
Lin, Cheng‐Han, Yu‐Chia Chen, Luo‐Ping Ger, et al.. (2022). Carboxyl-terminal modulator protein facilitates tumor metastasis in triple-negative breast cancer. Cancer Gene Therapy. 30(3). 404–413. 4 indexed citations
8.
Li, Hao‐Yi, Bing‐Chao Yan, Lixin Wei, Han‐Dong Sun, & Pema‐Tenzin Puno. (2021). Tangutidines A–C, Three Amphoteric Diterpene Alkaloids from Aconitum tanguticum. Natural Products and Bioprospecting. 11(4). 459–464. 5 indexed citations
9.
Kang, Hyun-Seo, Hao‐Yi Li, Shubo Zhao, et al.. (2020). DNA Structure-Specific Cleavage of DNA-Protein Crosslinks by the SPRTN Protease. Molecular Cell. 80(1). 102–113.e6. 43 indexed citations
10.
Zhao, Shubo, et al.. (2020). A ubiquitin switch controls autocatalytic inactivation of the DNA–protein crosslink repair protease SPRTN. Nucleic Acids Research. 49(2). 902–915. 29 indexed citations
11.
Lin, Cheng‐Han, Hao‐Yi Li, Yu‐Peng Liu, et al.. (2019). High-CLDN4 ESCC cells harbor stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma. Therapeutic Advances in Medical Oncology. 11. 3862490364–3862490364. 18 indexed citations
12.
Wang, Po‐Shun, Cheng‐Han Lin, Hui-Chuan Cheng, et al.. (2018). A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer. Oncogene. 37(34). 4662–4678. 66 indexed citations
13.
Li, Hao‐Yi, Yao-Lung Kuo, Hao-Hsien Lee, et al.. (2017). miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Research. 19(1). 133–133. 119 indexed citations
14.
Chen, Yu‐Chia, Hao‐Yi Li, Luo-Ping Ger, et al.. (2016). CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient. Oncotarget. 8(18). 29699–29710. 19 indexed citations
15.
Lin, Cheng‐Han, Forn-Chia Lin, Wei-Lun Chang, et al.. (2016). MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma. Oncotarget. 7(26). 39680–39693. 27 indexed citations
16.
Lin, Hung‐Yin, Jianzhou Chen, Hao‐Yi Li, & Chia‐Ning Yang. (2015). A simple three-input DNA-based system works as a full-subtractor. Scientific Reports. 5(1). 10686–10686. 14 indexed citations
17.
Li, Hao‐Yi, et al.. (2015). WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase. Cell Cycle. 14(3). 408–416. 28 indexed citations
18.
Wang, Shao‐An, Hao‐Yi Li, Tsung‐I Hsu, et al.. (2011). Heat Shock Protein 90 Stabilizes Nucleolin to Increase mRNA Stability in Mitosis. Journal of Biological Chemistry. 286(51). 43816–43829. 30 indexed citations
19.
Tseng, Chih-Hua, Cherng-Chyi Tzeng, Pei‐Jung Lu, et al.. (2010). Synthesis and Antiproliferative Evaluation of Certain Indeno[1,2-c]quinoline Derivatives. Part 2. Journal of Medicinal Chemistry. 53(16). 6164–6179. 71 indexed citations
20.
Shaw, Arthur Y., et al.. (2009). Synthesis of 2-styrylchromones as a novel class of antiproliferative agents targeting carcinoma cells. European Journal of Medicinal Chemistry. 44(6). 2552–2562. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuxin Qin Breakdown of academic impact, for papers by Jing-Yuan Liu Breakdown of academic impact, for papers by Boon Shing Tan Breakdown of academic impact, for papers by Jean‐François Gaussin Breakdown of academic impact, for papers by Sundar Neelakantan Breakdown of academic impact, for papers by Valentina Pileczki Breakdown of academic impact, for papers by Jacqueline Keßler Breakdown of academic impact, for papers by Zhiyu Li Breakdown of academic impact, for papers by Małgorzata Sztiller-Sikorska Breakdown of academic impact, for papers by Kwang-Rok Kim
Rankless by CCL
2026